We are pleased to announce that the OBN Awards has shortlisted Precision for Medicine, Oncology and Rare Disease as a finalist for Best Specialist CRO!
Each year, the OBN Awards celebrate the UK’s most innovative life sciences companies. Celebrating the 10th anniversary of the OBN Awards, OBN strives to keep the awards relevant by regularly updating the nomination categories and criteria. This year, OBN has created the “Best Specialist CRO” Award to recognize an outstanding contract research organization working in a niche area.
As an industry leader in clinical trials and drug development throughout Europe, with an emphasis on oncology and rare disease innovation, we are very pleased to have received this recognition. We look forward to the announcement of the winner when the annual OBN Awards are held on October 11 at the University of Oxford.
Congratulations, Precision for Medicine, Oncology and Rare Disease!
To see the complete list of OBN Awards and 2018 Finalists, please visit obn-awards.com.
OBN is a not-for-profit membership organization supporting innovative life sciences companies, corporate partners, and investors.
Precision for Medicine is part of the Precision Medicine Group, an integrated team of experts that extends Precision for Medicine’s therapeutic development capabilities beyond approval and into launch strategies, marketing communication, and payer insights. As one company, the Precision Medicine Group helps pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.
